MX2018013325A - Derivados de adenina como inhibidores de proteína quinasa. - Google Patents
Derivados de adenina como inhibidores de proteína quinasa.Info
- Publication number
- MX2018013325A MX2018013325A MX2018013325A MX2018013325A MX2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A
- Authority
- MX
- Mexico
- Prior art keywords
- protein kinase
- pharmaceutically acceptable
- formula
- diseases
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto adecuado para usarse como un inhibidor de cinasa de conformidad con la fórmula general (I) [compuesto (C), en lo sucesivo], o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo, fórmula (I) en donde A, R1, R2, R3, R3', R4, R4', X, Y, Z, T son como se define en las reivindicaciones; la invención además se refiere a un método in vitro para inhibir actividad de proteína cinasa que comprende poner en contacto una proteína cinasa con un compuesto de la fórmula (I), o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo; la invención además se refiere a los compuestos de la fórmula (I) por sí mismos, así como a su uso como un medicamente, y para usarse o en un método de tratamiento de una enfermedad mediada por una proteína cinasa seleccionada de cáncer, trastornos inflamatorios, enfermedades cardiovasculares, enfermedades inducidas virales, enfermedades circulatorias, enfermedades fibro-proliferativas y trastornos de sensibilización al dolor. (ver fórmula I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305530 | 2016-05-04 | ||
| PCT/EP2017/060730 WO2017191297A1 (en) | 2016-05-04 | 2017-05-04 | Adenine derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013325A true MX2018013325A (es) | 2019-08-16 |
Family
ID=55953089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013325A MX2018013325A (es) | 2016-05-04 | 2017-05-04 | Derivados de adenina como inhibidores de proteína quinasa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11236093B2 (es) |
| EP (1) | EP3452477B1 (es) |
| JP (1) | JP7485502B2 (es) |
| KR (1) | KR102479746B1 (es) |
| CN (1) | CN109311882B (es) |
| AU (1) | AU2017260298B9 (es) |
| CA (1) | CA3022896A1 (es) |
| EA (1) | EA201892460A1 (es) |
| IL (1) | IL262700B (es) |
| MX (1) | MX2018013325A (es) |
| SG (1) | SG11201809674QA (es) |
| WO (1) | WO2017191297A1 (es) |
| ZA (1) | ZA201808014B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2899114T3 (es) * | 2016-07-25 | 2022-03-10 | Nerviano Medical Sciences Srl | Análogos de purina y 3-deazapurina como inhibidores de colina cinasa |
| AU2018285833A1 (en) * | 2017-06-14 | 2020-01-02 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
| WO2020221334A1 (en) * | 2019-04-30 | 2020-11-05 | City University Of Hong Kong | Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
| CN112300180B (zh) * | 2019-07-26 | 2022-04-29 | 珠海宇繁生物科技有限责任公司 | 一种irak4激酶抑制剂及其制备方法 |
| CN111560389B (zh) * | 2020-06-11 | 2022-07-01 | 云南中烟工业有限责任公司 | 烟草丝裂原活化蛋白激酶基因NtMAPK8及其应用 |
| KR20240035395A (ko) | 2021-06-14 | 2024-03-15 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 사용할 수 있는 요소 유도체 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010404D0 (en) | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| US5994361A (en) * | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| US20050065171A1 (en) * | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| US20050250789A1 (en) * | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| TW201102389A (en) | 2009-04-14 | 2011-01-16 | Astellas Pharma Inc | Fused pyrroloprydine derivatives |
| EP2508607A1 (en) * | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| US9889180B2 (en) * | 2012-11-19 | 2018-02-13 | Agency For Science, Technology And Research | Method of treating cancer |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
-
2017
- 2017-05-04 EA EA201892460A patent/EA201892460A1/ru unknown
- 2017-05-04 EP EP17722013.4A patent/EP3452477B1/en active Active
- 2017-05-04 CN CN201780033173.5A patent/CN109311882B/zh active Active
- 2017-05-04 JP JP2018557916A patent/JP7485502B2/ja active Active
- 2017-05-04 US US16/097,805 patent/US11236093B2/en active Active
- 2017-05-04 SG SG11201809674QA patent/SG11201809674QA/en unknown
- 2017-05-04 CA CA3022896A patent/CA3022896A1/en active Pending
- 2017-05-04 MX MX2018013325A patent/MX2018013325A/es unknown
- 2017-05-04 WO PCT/EP2017/060730 patent/WO2017191297A1/en active Search and Examination
- 2017-05-04 AU AU2017260298A patent/AU2017260298B9/en active Active
- 2017-05-04 KR KR1020187034306A patent/KR102479746B1/ko active IP Right Grant
-
2018
- 2018-10-31 IL IL262700A patent/IL262700B/en unknown
- 2018-11-27 ZA ZA2018/08014A patent/ZA201808014B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201809674QA (en) | 2018-11-29 |
| US20190127379A1 (en) | 2019-05-02 |
| EP3452477C0 (en) | 2023-09-13 |
| CN109311882B (zh) | 2022-02-11 |
| KR20190003968A (ko) | 2019-01-10 |
| US11236093B2 (en) | 2022-02-01 |
| JP7485502B2 (ja) | 2024-05-16 |
| CN109311882A (zh) | 2019-02-05 |
| BR112018072468A2 (pt) | 2019-02-19 |
| AU2017260298B2 (en) | 2021-09-02 |
| WO2017191297A1 (en) | 2017-11-09 |
| ZA201808014B (en) | 2020-02-26 |
| EP3452477B1 (en) | 2023-09-13 |
| EA201892460A1 (ru) | 2019-09-30 |
| KR102479746B1 (ko) | 2022-12-21 |
| AU2017260298A1 (en) | 2018-12-13 |
| AU2017260298B9 (en) | 2021-09-30 |
| IL262700B (en) | 2022-02-01 |
| JP2019516688A (ja) | 2019-06-20 |
| IL262700A (en) | 2018-12-31 |
| EP3452477A1 (en) | 2019-03-13 |
| CA3022896A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| SA520411325B1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| CR20200441A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| SG10201903578VA (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| PL415078A1 (pl) | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта |